Retrophin, Inc. (RTRX) Reaches $27.99 After 6.00% Up Move; Shorts at Collegium Pharmaceutical (COLL) Lowered By 10.04%

May 18, 2018 - By Robert Davis

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Logo

Collegium Pharmaceutical Inc (NASDAQ:COLL) had a decrease of 10.04% in short interest. COLL’s SI was 2.38M shares in May as released by FINRA. Its down 10.04% from 2.65 million shares previously. With 424,600 avg volume, 6 days are for Collegium Pharmaceutical Inc (NASDAQ:COLL)’s short sellers to cover COLL’s short positions. The SI to Collegium Pharmaceutical Inc’s float is 10.95%. The stock increased 0.50% or $0.12 during the last trading session, reaching $25.33. About 146,484 shares traded. Collegium Pharmaceutical, Inc. (NASDAQ:COLL) has risen 133.98% since May 18, 2017 and is uptrending. It has outperformed by 122.43% the S&P500.

The stock of Retrophin, Inc. (NASDAQ:RTRX) is a huge mover today! The stock increased 2.64% or $0.72 during the last trading session, reaching $27.99. About 115,479 shares traded. Retrophin, Inc. (NASDAQ:RTRX) has risen 22.54% since May 18, 2017 and is uptrending. It has outperformed by 10.99% the S&P500.The move comes after 9 months positive chart setup for the $1.12 billion company. It was reported on May, 18 by Barchart.com. We have $29.67 PT which if reached, will make NASDAQ:RTRX worth $67.08 million more.

Investors sentiment decreased to 1.13 in Q4 2017. Its down 0.49, from 1.62 in 2017Q3. It fall, as 11 investors sold Retrophin, Inc. shares while 37 reduced holdings. 18 funds opened positions while 36 raised stakes. 38.84 million shares or 3.08% less from 40.07 million shares in 2017Q3 were reported. Rhumbline Advisers reported 0% in Retrophin, Inc. (NASDAQ:RTRX). Virginia Retirement Et Al has 0.01% invested in Retrophin, Inc. (NASDAQ:RTRX). Ameriprise Financial Incorporated has invested 0% in Retrophin, Inc. (NASDAQ:RTRX). Ajo L P holds 28,395 shares or 0% of its portfolio. Bnp Paribas Arbitrage Sa has 0% invested in Retrophin, Inc. (NASDAQ:RTRX) for 8,006 shares. Voya Investment Management Lc reported 0% of its portfolio in Retrophin, Inc. (NASDAQ:RTRX). 277,091 were reported by Century. Oak Ridge Invests Ltd, Illinois-based fund reported 491,906 shares. Goldman Sachs Gp accumulated 0% or 611,562 shares. Td Asset Mngmt owns 10,800 shares or 0% of their US portfolio. Spark Inv Mngmt Ltd Liability Corp, a New York-based fund reported 327,800 shares. Price T Rowe Assocs Inc Md reported 286,201 shares stake. State Board Of Administration Of Florida Retirement Sys accumulated 0% or 23,805 shares. Parallax Volatility Advisers Lp, California-based fund reported 5,796 shares. Jacobs Levy Equity Mngmt has 22,400 shares.

Among 4 analysts covering Retrophin (NASDAQ:RTRX), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Retrophin had 8 analyst reports since August 12, 2015 according to SRatingsIntel. The firm has “Buy” rating by Zacks given on Wednesday, August 12. The firm has “Outperform” rating by BMO Capital Markets given on Wednesday, April 4. The stock of Retrophin, Inc. (NASDAQ:RTRX) has “Buy” rating given on Tuesday, November 7 by BMO Capital Markets. The stock of Retrophin, Inc. (NASDAQ:RTRX) has “Outperform” rating given on Tuesday, April 12 by BMO Capital Markets. JMP Securities initiated the stock with “Mkt Outperform” rating in Monday, November 2 report. The stock of Retrophin, Inc. (NASDAQ:RTRX) has “Buy” rating given on Friday, October 6 by BMO Capital Markets.

Since January 5, 2018, it had 0 insider purchases, and 2 sales for $44,878 activity. The insider ROTE WILLIAM E. sold 1,034 shares worth $22,232. Another trade for 942 shares valued at $22,646 was made by REED ELIZABETH E on Friday, January 5.

More news for Retrophin, Inc. (NASDAQ:RTRX) were recently published by: Globenewswire.com, which released: “Retrophin Reports First Quarter 2018 Financial Results” on May 01, 2018. Seekingalpha.com‘s article titled: “Retrophin’s (RTRX) CEO Steve Aselage on Q1 2018 Results – Earnings Call Transcript” and published on May 02, 2018 is yet another important article.

Retrophin, Inc., a biopharmaceutical company, focuses on the development, acquisition, and commercialization of therapies for the treatment of serious or rare diseases. The company has market cap of $1.12 billion. The Company’s marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in well-opacifying gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, and for adjunctive treatment of patients with peroxisomal disorders; and Thiola, a tiopronin tablet for the treatment of cystinuria. It currently has negative earnings. The companyÂ’s product candidates consist of Sparsentan, which is in Phase III clinical trial for the treatment of focal segmental glomerulosclerosis; Fosmetpantotenate, a novel small molecule that is in Phase III clinical trial to treat pantothenate kinase-associated neurodegeneration; Tetracosactide Zinc , a synthetic hormone analog that is in preclinical stage; and Liquid Ursodeoxycholic Acid, a liquid formulation of ursodeoxycholic acid, which is in preclinical stage to treat primary biliary cholangitis.

Analysts await Retrophin, Inc. (NASDAQ:RTRX) to report earnings on August, 8. They expect $-0.40 EPS, down 17.65% or $0.06 from last year’s $-0.34 per share. After $-0.46 actual EPS reported by Retrophin, Inc. for the previous quarter, Wall Street now forecasts -13.04% EPS growth.

Among 7 analysts covering Collegium Pharmaceutical Inc (NASDAQ:COLL), 7 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Collegium Pharmaceutical Inc had 18 analyst reports since February 19, 2016 according to SRatingsIntel. On Friday, July 14 the stock rating was maintained by Jefferies with “Buy”. Janney Capital maintained Collegium Pharmaceutical, Inc. (NASDAQ:COLL) rating on Monday, November 6. Janney Capital has “Buy” rating and $21.0 target. The firm has “Buy” rating given on Monday, February 12 by Piper Jaffray. The stock of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) earned “Buy” rating by Piper Jaffray on Thursday, December 7. Gabelli initiated Collegium Pharmaceutical, Inc. (NASDAQ:COLL) on Tuesday, September 13 with “Buy” rating. The firm earned “Buy” rating on Wednesday, October 18 by Jefferies. The company was maintained on Friday, June 9 by Janney Capital. On Thursday, December 14 the stock rating was maintained by Piper Jaffray with “Buy”. The firm earned “Buy” rating on Tuesday, July 25 by Piper Jaffray. The rating was maintained by Jefferies on Sunday, February 11 with “Buy”.

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes abuse-deterrent products that incorporate its DETERx platform technology for the treatment of chronic pain and other diseases. The company has market cap of $836.84 million. It offers Xtampza, an oral formulation of oxycodone, for the management of pain. It currently has negative earnings. The firm also develops Onsolis, a transmucosal immediate-release fentanyl film indicated for the management of breakthrough pain in cancer patients 18 years of age and older.

Retrophin, Inc. (NASDAQ:RTRX) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: